NPI 2358 clinical trials
Also written Plinabulin, NPI-2358 and BPI-2358.
How each study uses NPI 2358 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the NPI 2358 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 7
BeyondSpring Pharmaceuticals Inc. (6) · Nereus Pharmaceuticals, Inc. (2) · Peking Union Medical College Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Salma Sabbour (1) · Lyudmila Bazhenova, M.D. (1) · Xiaorong Dong (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Docetaxel (1) · Pegfilgrastim (1) · Etoposide (1) · Platinum Compounds (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test NPI 2358.
- Nov 2026Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Phase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses NPI 2358 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)Not yet recruitingPhase 3BeyondSpring Pharmaceuticals Inc.NCT07361484Written as Plinabulin
- First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCRecruitingPhase 2Xiaorong DongNCT05745350Written as Pembrolizumab, Plinabulin plus Etoposide and Platinum
- Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Active, not recruitingPhase 2Peking Union Medical College HospitalNCT05599789Written as Pembrolizumab in Combination with Plinabulin and Docetaxel
- Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCCompletedPhase 3BeyondSpring Pharmaceuticals Inc.NCT02504489Written as Docetaxel + Plinabulin (DP)
- Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04902040Written as Plinabulin
- A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerCompletedPhase 1/2Salma SabbourNCT03575793Written as Plinabulin
- Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)Active, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05130827Written as Plinabulin
- Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1Lyudmila Bazhenova, M.D.NCT02812667Written as Nivolumab + Plinabulin
- Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3CompletedPhase 3BeyondSpring Pharmaceuticals Inc.NCT03102606Written as Plinabulin
- Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2CompletedPhase 2BeyondSpring Pharmaceuticals Inc.NCT04345900Written as Plinabulin
- Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced NeutropeniaActive, not recruitingPhase 3BeyondSpring Pharmaceuticals Inc.NCT03294577Written as Plinabulin
- Plinabulin iv Solution in Prevention of TAC Induced NeutropeniaCompletedPhase 2BeyondSpring Pharmaceuticals Inc.NCT04227990Written as Plinabulin
- Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerTerminatedPhase 1/2University of WashingtonNCT02846792Written as Plinabulin
- Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 1/2Nereus Pharmaceuticals, Inc.NCT00630110Written as NPI-2358 + docetaxel
- Study of the Vascular Disrupting Agent NPI-2358 in Patients With Advanced Solid Tumors or LymphomaCompletedPhase 1Nereus Pharmaceuticals, Inc.NCT00322608Written as NPI-2358
Codes
What other systems call NPI 2358 · ClinicalTrials.gg INT004981
- MeSH (NLM) C514351NPI 2358One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C514351 | NPI 2358 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.